Evolving First-Line Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.
Simple Summary: Hormone receptor-positive, HER2-negative metastatic breast cancer, the most common type of advanced breast cancer, depends on estrogen to grow. Treatments that block this hormone remain the basis of care, especially when combined with newer drugs (CDK4/6 inhibitors) that slow cancer...
| Publicado en: | Current Oncology Vol. 33; no. 7; pp. 421 - 442 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |